AR123855A1 - PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE - Google Patents

PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE

Info

Publication number
AR123855A1
AR123855A1 ARP210102890A ARP210102890A AR123855A1 AR 123855 A1 AR123855 A1 AR 123855A1 AR P210102890 A ARP210102890 A AR P210102890A AR P210102890 A ARP210102890 A AR P210102890A AR 123855 A1 AR123855 A1 AR 123855A1
Authority
AR
Argentina
Prior art keywords
cdr
seq
amino acid
acid sequence
peg
Prior art date
Application number
ARP210102890A
Other languages
Spanish (es)
Inventor
Wei Liang
- Lin Weiyu Ching
Yan Wu
Minhong Yan
Breanna Sachiko Vollmar
Mingjian Fei
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR123855A1 publication Critical patent/AR123855A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Reivindicación 1: Un anticuerpo PEGilado que se une a MerTK, en donde el anticuerpo está conjugado con uno o más polímeros de polietilenglicol (PEG); en donde cada uno de los polímeros de PEG está conjugado con una cadena pesada o cadena liviana del anticuerpo en un residuo de cisteína modificada por ingeniería genética; y en donde el anticuerpo comprende: (1) un dominio variable de la cadena pesada (VH) que comprende (a) una CDR-H1 que comprende la secuencia de aminoácidos de SYAMG (SEQ ID Nº 1), (b) una CDR-H2 que comprende la secuencia de aminoácidos de IINSYGNTYYANWAKG (SEQ ID Nº 2), y (c) una CDR-H3 que comprende la secuencia de aminoácidos de DPGVSSNL (SEQ ID Nº 3), y un dominio variable de la cadena liviana (VL) que comprende (d) una CDR-L1 que comprende la secuencia de aminoácidos de QASQNIYSGLA (SEQ ID Nº 4), (e) una CDR-L2 que comprende la secuencia de aminoácidos de GASKLAS (SEQ ID Nº 5), y (f) una CDR-L3 que comprende la secuencia de aminoácidos de QATYYSSNSVA (SEQ ID Nº 6); o (2) un dominio variable de la cadena pesada (VH) que comprende (a) una CDR-H1 que comprende la secuencia de aminoácidos de ANTMN (SEQ ID Nº 7), (b) una CDR-H2 que comprende la secuencia de aminoácidos de IFTATGSTYYATWVNG (SEQ ID Nº 8), y (c) una CDR-H3 que comprende la secuencia de aminoácidos de SGSGSSSGAFNI (SEQ ID Nº 9), y un dominio variable de la cadena liviana (VL) que comprende (d) una CDR-L1 que comprende la secuencia de aminoácidos de QASQSISSSLA (SEQ ID Nº 10), (e) una CDR-L2 que comprende la secuencia de aminoácidos de AASILAS (SEQ ID Nº 11), y (f) una CDR-L3 que comprende la secuencia de aminoácidos de QCTSYGSLFLGP (SEQ ID Nº 12).Claim 1: A PEGylated antibody that binds MerTK, wherein the antibody is conjugated to one or more polyethylene glycol (PEG) polymers; wherein each of the PEG polymers is conjugated to an antibody heavy chain or light chain at an engineered cysteine residue; and wherein the antibody comprises: (1) a heavy chain (VH) variable domain comprising (a) a CDR-H1 comprising the SYAMG amino acid sequence (SEQ ID NO: 1), (b) a CDR- H2 comprising the amino acid sequence of IINSYGNTYYANWAKG (SEQ ID NO 2), and (c) a CDR-H3 comprising the amino acid sequence of DPGVSSNL (SEQ ID NO 3), and a light chain (VL) variable domain. comprising (d) a CDR-L1 comprising the amino acid sequence of QASQNIYSGLA (SEQ ID NO: 4), (e) a CDR-L2 comprising the amino acid sequence of GASKLAS (SEQ ID NO: 5), and (f) a CDR-L3 comprising the amino acid sequence of QATYYSSNSVA (SEQ ID NO: 6); or (2) a heavy chain (VH) variable domain comprising (a) a CDR-H1 comprising the amino acid sequence of ANTMN (SEQ ID NO: 7), (b) a CDR-H2 comprising the sequence of amino acids of IFTATGSTYYATWVNG (SEQ ID NO: 8), and (c) a CDR-H3 comprising the amino acid sequence of SGSGSSSGAFNI (SEQ ID NO: 9), and a light chain (VL) variable domain comprising (d) a CDR-L1 comprising the amino acid sequence of QASQSISSSLA (SEQ ID No. 10), (e) a CDR-L2 comprising the amino acid sequence of AASILAS (SEQ ID No. 11), and (f) a CDR-L3 comprising the amino acid sequence of QCTSYGSLFLGP (SEQ ID NO: 12).

ARP210102890A 2020-10-20 2021-10-19 PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE AR123855A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063094197P 2020-10-20 2020-10-20

Publications (1)

Publication Number Publication Date
AR123855A1 true AR123855A1 (en) 2023-01-18

Family

ID=78725615

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102890A AR123855A1 (en) 2020-10-20 2021-10-19 PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE

Country Status (3)

Country Link
AR (1) AR123855A1 (en)
TW (1) TW202233671A (en)
WO (1) WO2022086957A1 (en)

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US830930A (en) 1905-11-22 1906-09-11 E & T Fairbanks & Co Weighing-scale.
US1624821A (en) 1926-03-26 1927-04-12 Sidney C Ashton Oil-well pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2 Inc CHANGED ANTIBODIES.
JP2919890B2 (en) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DK0590058T3 (en) 1991-06-14 2004-03-29 Genentech Inc Humanized heregulin antibody
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ES2246069T3 (en) 1997-05-02 2006-02-01 Genentech, Inc. PROCEDURE FOR THE PREPARATION OF MULTI-SPECIFIC ANTIBODIES THAT HAVE COMMON AND MULTIMERIC COMPONENTS.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1998058964A1 (en) 1997-06-24 1998-12-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ES2375931T3 (en) 1997-12-05 2012-03-07 The Scripps Research Institute HUMANIZATION OF ANTIBODY MURINO.
JP2002510481A (en) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001007611A2 (en) 1999-07-26 2001-02-01 Genentech, Inc. Novel polynucleotides and method for the use thereof
MXPA02003456A (en) 1999-10-04 2002-10-23 Medicago Inc Method for regulating transcription of foreign genes in the presence of nitrogen.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2003531588A (en) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド Multivalent antibodies and their uses
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ES2326964T3 (en) 2001-10-25 2009-10-22 Genentech, Inc. GLICOPROTEIN COMPOSITIONS.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
BR0309145A (en) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Cells from which the genome is modified
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
US20060121562A1 (en) 2002-06-28 2006-06-08 Jiing-Ren Liou Human receptor tyrosine kinase mertk
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PL212899B1 (en) 2002-12-16 2012-12-31 Genentech Inc Immunoglobulin variants and uses thereof
NZ603037A (en) 2003-01-22 2014-05-30 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JP5128935B2 (en) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド Humanized anti-TGF-β antibody
EP2360186B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
DK1871805T3 (en) 2005-02-07 2019-12-02 Roche Glycart Ag ANTI-BINDING MOLECULES BINDING EGFR, VECTORS CODING THEREOF, AND APPLICATIONS THEREOF
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
EP1907424B1 (en) 2005-07-01 2015-07-29 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
PL2059533T3 (en) 2006-08-30 2013-04-30 Genentech Inc Multispecific antibodies
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
RU2531758C2 (en) 2008-02-11 2014-10-27 Куретек Лтд. Monoclonal antibodies for tumour treatment
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US20110223188A1 (en) 2008-08-25 2011-09-15 Solomon Langermann Targeted costimulatory polypeptides and methods of use to treat cancer
PL2376535T3 (en) 2008-12-09 2017-09-29 F.Hoffmann-La Roche Ag Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2225932B1 (en) 2009-03-03 2013-01-23 Institut de Recherche pour le Développement ( IRD) Method for enhancing market garden plant growth
BRPI1014089A2 (en) 2009-04-02 2016-04-19 Roche Glycart Ag multispecific antibodies comprising full length antibodies and single chain fab fragments
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
CA2761233A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN101606769A (en) 2009-07-15 2009-12-23 陈德芳 A kind of gemstone connecting structure
JP2013512251A (en) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Simultaneous inhibition of PD-L1 / PD-L2
SI3279215T1 (en) 2009-11-24 2020-07-31 Medimmune Limited Targeted binding agents against b7-h1
KR101839163B1 (en) 2010-06-08 2018-03-15 제넨테크, 인크. Cysteine engineered antibodies and conjugates
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
DK2691417T3 (en) 2011-03-29 2018-11-19 Roche Glycart Ag ANTIBODY FC VARIANTS
KR101970025B1 (en) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Antibodies and other molecules that bind b7-h1 and pd-1
US9096642B2 (en) 2011-06-08 2015-08-04 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
RS57744B1 (en) 2011-08-23 2018-12-31 Roche Glycart Ag Bispecific antigen binding molecules
CN202382282U (en) 2011-09-30 2012-08-15 张伟生 Energy-saving gas stove
JP6152120B2 (en) 2012-02-15 2017-06-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Affinity chromatography based on Fc receptors
CN104159911A (en) 2012-03-07 2014-11-19 奥瑞基尼探索技术有限公司 Peptidomimetic compounds as immunomodulators
EP3553086A1 (en) 2012-05-31 2019-10-16 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
PL2992012T3 (en) 2013-04-29 2019-12-31 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
WO2014179664A2 (en) 2013-05-02 2014-11-06 Anaptysbio, Inc. Antibodies directed against programmed death-1 (pd-1)
CN111423511B (en) 2013-05-31 2024-02-23 索伦托药业有限公司 Antigen binding proteins that bind to PD-1
CN104250302B (en) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 The anti-antibody of PD 1 and its application
CN103650585B (en) 2013-07-08 2017-11-21 华为技术有限公司 A kind of method and apparatus of cell switching
JP2016532711A (en) 2013-09-06 2016-10-20 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Derivatives of 1,3,4-oxadiazole and 1,3,4-thiadiazole as immunomodulators
PL3363790T3 (en) 2013-09-06 2020-07-27 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
MX2016003292A (en) 2013-09-13 2016-06-24 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics.
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
SI3081576T1 (en) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
CA2931113C (en) 2013-12-20 2023-07-11 Genentech, Inc. Antibodies comprising an antigen-binding site that specifically binds to two different epitopes and methods of making them
TWI680138B (en) 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
EP3102605B1 (en) 2014-02-04 2018-11-14 Pfizer Inc Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
ES2783026T3 (en) 2014-02-04 2020-09-16 Pfizer Combination of a PD-1 antagonist and a 4-1BB agonist for the treatment of cancer
UA117289C2 (en) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Multispecific antibodies
AU2015283802A1 (en) 2014-06-30 2017-02-16 Acn 616 222 309 Pty Ltd System and method for rendering buildings in three dimensions
WO2016016299A1 (en) 2014-07-29 2016-02-04 F. Hoffmann-La Roche Ag Multispecific antibodies
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
KR20170052600A (en) 2014-09-12 2017-05-12 제넨테크, 인크. Cysteine engineered antibodies and conjugates
CN107001478B (en) 2014-10-14 2022-01-11 诺华股份有限公司 Antibody molecules against PD-L1 and uses thereof
US10949507B2 (en) 2014-10-17 2021-03-16 Vulpecula, Llc. Methods, systems, and computer program products for web browsing
BR112017011536A2 (en) 2014-12-02 2018-02-27 Celgene Corp combination therapies
CN107787332B (en) 2015-04-24 2022-09-09 豪夫迈·罗氏有限公司 Multispecific antigen binding proteins
CN114364703A (en) * 2019-04-19 2022-04-15 豪夫迈·罗氏有限公司 Anti-merk antibodies and methods of use thereof

Also Published As

Publication number Publication date
WO2022086957A1 (en) 2022-04-28
TW202233671A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
ES2523740T3 (en) Monoclonal antibodies to the fibroblast growth factor 2 receptor
PE20211863A1 (en) BISPECIFIC ANTIGEN BINDING MOLECULES INCLUDING CLONE 212 ANTI-FAP
AR065506A1 (en) OX40 ANTAGONIST ANTIBODIES AND ITS USE IN THE TREATMENT OF DISEASES
PE20221869A1 (en) BISECIFIC ANTIGEN-BINDING MOLECULES DIRECTED TO OX40 AND PAF
AR110659A1 (en) ANTI-NEUROPILIN ANTIGENS PROTEINS AND METHOD FOR USE
AR088579A1 (en) FORMULATIONS OF ANTIBODIES
PE20080980A1 (en) ANTI-LYMPHOTOXIN ALPHA ANTIBODIES
PE20141186A1 (en) TNF-ALPHA BINDING PROTEINS
PE20120211A1 (en) ANTIBODIES THAT HAVE HUMAN OX40 SPECIFICITY
RS54197B1 (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
AR080243A1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT
PE20140848A1 (en) MONOCLONAL ANTIBODIES AGAINST RGMA PROTEIN AND ITS USES
PE20211709A1 (en) ANTIBODIES THAT RECOGNIZE TAU
PE20220279A1 (en) SPECIFIC INHIBITORS OF THE LTBP COMPLEX OF TGF BETA AND USES THEREOF
NZ596712A (en) Anti cxcr4 antibodies for the treatment of hiv
RU2019124709A (en) COMPOSITIONS AND METHODS ASSOCIATED WITH DESIGNED CONSTRUCTIONS BASED ON Fc-ANTIGEN BINDING DOMAIN
PE20121645A1 (en) COMPOSITIONS AND METHODS TO TREAT INFLAMMATORY DISORDERS
CO6180454A2 (en) ANTIBODIES OF EGFL7 AND METHODS OF USE
PE20230844A1 (en) ANTI-NECTIN-4 ANTIBODY, CONJUGATE WHICH INCLUDES IT AND APPLICATION THEREOF
RU2018106456A (en) ANTIBODY TO EPHA4
PE20231504A1 (en) SPECIFIC ANTIBODIES FOR KRAS AND THEIR USES
PE20230408A1 (en) ANTI-LILRB1 ANTIBODY AND USES THEREOF
AR115192A1 (en) ANTIBODIES
RU2021128024A (en) METHODS FOR CULTIVATION OF CELLS
AR123855A1 (en) PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE

Legal Events

Date Code Title Description
FB Suspension of granting procedure